Jade Biosciences, Inc. 8-K

What Happened
Jade Biosciences, Inc. announced its financial results for the quarter and year ended December 31, 2025 via a press release issued March 6, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8‑K (Item 2.02) filed the same day (Accession No. 0001193125-26-094967).

Key Details

• Filed Form 8‑K on March 6, 2026 reporting results of operations and financial condition (Item 2.02).
• Results cover the quarter and full year ended December 31, 2025.
• Press release with the financial results is attached as Exhibit 99.1 to the 8‑K.
• The filing includes the interactive cover page XBRL file (Exhibit 104).

Why It Matters
This 8‑K is the company’s official public disclosure of its quarterly and full‑year 2025 earnings and financial condition. For investors, the press release will contain the concrete earnings, revenue, expense and cash‑flow figures, plus any commentary on business trends or guidance that could affect valuation or near‑term share performance. Retail investors should read the attached press release and any accompanying financial statements for the specific metrics and management commentary.